Dr. Kumar on Next Steps for Venetoclax in Multiple Myeloma

Shaji K. Kumar, MD
Published: Thursday, Feb 09, 2017



Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the next steps for venetoclax (Venclexta) in the treatment of patients with multiple myeloma.

Venetoclax, a BCL-2 inhibitor, has been generally well tolerated in trials, says Kumar. Toxicities have been manageable, suggesting it would be an option to explore in combination regimens.

According to Kumar, next steps include identifying a subset of patients who are sensitive to the drug through a multi-pronged approach of the combination of venetoclax plus dexamethasone in relapsed multiple myeloma.

Currently, a phase III trial is accruing to evaluate the combination of venetoclax and bortezomib (Velcade) as well.
 


Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the next steps for venetoclax (Venclexta) in the treatment of patients with multiple myeloma.

Venetoclax, a BCL-2 inhibitor, has been generally well tolerated in trials, says Kumar. Toxicities have been manageable, suggesting it would be an option to explore in combination regimens.

According to Kumar, next steps include identifying a subset of patients who are sensitive to the drug through a multi-pronged approach of the combination of venetoclax plus dexamethasone in relapsed multiple myeloma.

Currently, a phase III trial is accruing to evaluate the combination of venetoclax and bortezomib (Velcade) as well.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x